ARMP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Armata Pharmaceuticals Inc (ARMP) shows some positive developments, such as the FDA QIDP designation and a planned Phase 3 study, but its financial performance is weak, with declining revenue and significant net losses. The technical indicators are mixed, with bullish moving averages but a high RSI suggesting the stock may be overbought. Given the beginner investor's long-term focus and the lack of strong immediate buy signals, holding off on purchasing ARMP at this time is recommended.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.29, indicating upward momentum. However, the RSI_6 is at 70.756, suggesting the stock is nearing overbought territory. Key support is at 8.036, and resistance is at 11.455.
FDA QIDP designation for AP-SA02, granting five years of market exclusivity and potential for expedited approval.
$26.2 million Department of Defense grant supporting clinical development.
Planned Phase 3 superiority study for AP-SA02 in late 2026.
Significant revenue decline (-61.02% YoY in Q3 2025).
High net losses (-$26.67 million in Q3 2025).
No significant hedge fund or insider trading activity.
In Q3 2025, revenue dropped by 61.02% YoY to $1.16 million. However, net income improved to -$26.67 million (up 386.68% YoY), and EPS increased to -0.74 (up 393.33% YoY). Gross margin remained at 100%.
Analysts are bullish on ARMP, with two recent Buy ratings and a price target increase to $15. Analysts highlight the company's proprietary phage platform and in-house manufacturing as differentiators in the clinical-stage phage therapy market.
